Antonina I. Chertkova

Antonina I. Chertkova

Auto-generated profile, based on publicly available information

Antonina I. Chertkova

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 October 2021 in Russian Journal of Biotherapy
Verified
Journal Article
Open access
PDF file
TZT. N. Zabotina
T. N. Zabotina
ACA. I. Chertkova
A. I. Chertkova
ABA. A. Borunova
A. A. Borunova
EZE. N. Zakharova
E. N. Zakharova
ESE. K. Shoua
E. K. Shoua
AKA. G. Kadagidze
A. G. Kadagidze
Introduction. Breast cancer (BC) is an immunogenic tumor. Immune cells infiltration of tumor tissue can affect the clinical course of the disease. The immunogenicity of breast cancer varies depending on the molecular subtype.The aim of this work was to study the main indicators of systemic and local immunity before patient’s treatment and to determine their relationship with the immediate neoadjuvant chemotherapy results.Materials and methods. Patients with stage II–III BC received standard neoadjuvant chemotherapy in accordance with the molecular subtypes. The percentage of the main effector and regulatory lymphocytes populations of systemic and local immunity was determined by flow cytometry.Results. A decrease in the level of effector CD8 and CD4 lymphocyte populations and an increase in the level suppressor populations in tumor tissue in comparison with peripheral blood indicate an immunosuppressive state of local immunity in BC patients. In tumor tissue, a high level of CD8+ PD-1+ and CD4+ PD-1+ cells were associated with a high level of regulatory CD4+ CD25highCD127–/low and CD8+ CD11b– CD28– lymphocytes. Differences were found in the significance of individual lymphocyte populations for the immediate results of treatment between patients with different subtypes of breast cancer.Conclusion. Determination of lymphocyte subpopulations correlating with the level of PD-1 cells, and the results of treatment in patients with different molecular BC subtypes, will help a clearer understanding of the antitumor immune response in this pathology, and will also serve as a basis for identifying immune biomarkers that can be used as additional predictive factors in various treatment options for BC patients.

1 January 2021 in Immunologiya
Verified
Journal Article
Closed access
ZKZ.G. Kadagidze
Z.G. Kadagidze
NFN.N. Blokhin National Medical Research Center of Oncology» of Ministry of Health of the Russian Federation
N.N. Blokhin National Medical Research Center of Oncology» of Ministry of Health of the Russian Federation
ACA.I. Chertkova
A.I. Chertkova
TZT.N. Zabotina
T.N. Zabotina
OGO.O. Gordeeva
O.O. Gordeeva
DTDmitrii V. Tabakov
Dmitrii V. Tabakov

8 December 2020 in Russian Journal of Biotherapy
Verified
Journal Article
Open access
PDF file
ABA. A. Borunova
A. A. Borunova
TZT. N. Zabotina
T. N. Zabotina
ESE. K. Shoua
E. K. Shoua
GCG. Z. Chkadua
G. Z. Chkadua
ACA. I. Chertkova
A. I. Chertkova
ZKZ. G. Kadagidze
Z. G. Kadagidze
Introduction. Long-term monitoring of immune system parameters in cancer patient in FSBI “N.N. Blokhin Medical Research Center of Oncology” of the Ministry of Health of Russia, as well as the absence of an immunological research algorithm and a spectrum of significant markers, served as the basis for this study.Purpose. To present reference values and determine the normal range for subpopulations of systemic immunity lymphocytes.Materials and methods. The phenotype of peripheral blood lymphocytes was studied in 186 healthy donors (86 men and 100 women), mean age 41,9 ± 12,5 years. To assess the multivariate phenotype by flow cytometry, monoclonal antibodies to CD45, CD3, CD4, CD8, CD16, CD56, CD19, CD25, CD28, CD11b, CD127, HLA-Dr, TCR-γ / δ, Perforin and Granzime B labeled various fluorochromes.Results. A panel of markers of immunocompetent cells of systemic immunity was developed as a basis for assessing the state of the immune system of cancer patients. Reference values and normal boundaries are given for characterizing the linearity of cells with detailing of the phenotypic and functional heterogeneity of the population of CD8+-lymphocytes, activation markers and the pool of naive cells; characteristics of various types of regulatory cells, functional activity of cells of the effector link of immunity. A comparative analysis of immunoregulatory indices was carried out and the vulnerability of the formula CD3+CD4+/CD3+CD8+ to the CD4+/CD8+ index was proved.Conclusion. The spectrum of the proposed indicators is the product of many years of research carried out in the laboratory of clinical immunology of the Federal State Budgetary Institution “N.N. Blokhin National Medical Research Center of Oncology” оf the Ministry of Health of the Russian Federation, in order to search for significant criteria for assessing the state of the immune system in cancer.

22 March 2020 in Russian Journal of Biotherapy
Verified
Journal Article
Open access
PDF file
ACA. I. Chertkova
A. I. Chertkova
TZT. N. Zabotina
T. N. Zabotina
VTV. T. Tsiklauri
V. T. Tsiklauri
EZE. N. Zakharova
E. N. Zakharova
DTDmitrii V. Tabakov
Dmitrii V. Tabakov
ZKZ. G. Kadagidze
Z. G. Kadagidze
Introduction. Age is considered as an important clinical and pathological factor in cancer patients. Malignant tumors are more likely to develop in older people, but the disease is less aggressive than in young patients. According to various authors, the influence of age on the development of tumors largely depends on the age-related features of the immune system.The aim of the present study was to determine the relationship of indicators of systemic antitumor immune response with the age of patients with primary operable breast cancer and cancer of the oral mucosa.Materials and methods. The study included patients with all subtypes of primary-operable breast cancer (n = 145) and patients with cancer of the oral mucosa (n = 29). Immunophenotyping of peripheral blood lymphocytes was performed using a wide panel of monoclonal antibodies to markers of adaptive and innate immunity cells.Results. In elder patients (40 years and older) with primary-operable breast cancer, the percentage of activated CD25+ lymphocytes and CD4+CD25+ and CD3+CD4+ T cells, NKT cells, activated HLA-DR+ lymphocytes, including activated CD3+HLA-DR+ T cells before treatment, was statistically significantly higher than in patients younger than 40 years. Patients of this group showed increase of CD8+CD - 11b+CD28– CTLs and a decrease in the number of naive lymphocytes (CD4 – CD62L+ and CD8+CD11b – CD28+) in comparison with control percentage, and the downward trend in CD4+CD25+CD127– Treg, with increased numbers of CD4+CD25+ T cells. In patients with cancer of the oral mucosa, an increase in the number of cells of some populations of the immune effector link and a decrease in the number of suppressor lymphocytes were revealed with age.Conclusion. The results suggest that age-related differences in the state of systemic antitumor immune response contribute to a more favorable course of breast cancer and some other malignancies in older persons. It is obvious that the features of age differences in the immune response to the tumor should be taken into account when prescribing systemic therapy, including immunotherapy.All patients gave written informed consent to participate in the study

1 January 2020 in Immunologiya
Verified
Journal Article
Closed access
NFN.N. Blokhin National Medical Research Center of Oncology of Ministry of Health of the Russian Federation
N.N. Blokhin National Medical Research Center of Oncology of Ministry of Health of the Russian Federation
TZT.N. Zabotina
T.N. Zabotina
ACA.I. Chertkova
A.I. Chertkova
ZKZ.G. Kadagidze
Z.G. Kadagidze
ABA.A. Borunova
A.A. Borunova
AMA.A. Meshcheryakov
A.A. Meshcheryakov

10 December 2023 in Journal of Modern Oncology
Verified
Journal Article
Open access
PDF file
TZTatiana N. Zabotina
Tatiana N. Zabotina
ACAntonina I. Chertkova
Antonina I. Chertkova
ABAnna A. Borunova
Anna A. Borunova
NKNikolay E. Kushlinskii
Nikolay E. Kushlinskii
EGElena S. Gershtein
Elena S. Gershtein
ХВХорошилов Максим Викторович
Хорошилов Максим Викторович
Background. The PD-1/PD-L1 pathway plays an important role in tumor evasion from immunological surveillance. In addition to the membrane forms of PD-1 and PD-L1, there are soluble variants: sPD-1 and sPD-L1. Both membrane and soluble forms have immunoregulatory properties and can affect the function and number of different immune cell populations. Aim. To study the relationship between the initial level of CD8⁺PD-1⁺ and CD4+PD-1⁺ lymphocytes and soluble forms of sPD-1 and sPD-L1 with the percentage of the main effector and regulatory populations of peripheral blood (PB) lymphocytes and tumor-infiltrating lymphocytes. Materials and methods. The study included melanoma, breast cancer and the oral mucosa cancer patients. The percentage of cell populations of PB lymphocytes and tumor-infiltrating lymphocytes was determined by flow cytometry before treatment. The concentrations of sPD-1 and sPD-L1 proteins were studied in blood serum using enzyme immunoassay. Results. The relationship of the level of CD8⁺PD-1⁺ cells with certain populations of CD8-lymphocytes in PB and tumor tissue was found. In the PB of melanoma patients with CD8⁺CD11b⁺CD28⁺ and CD8⁺CD11b⁻CD28⁻ T cells, in breast cancer patients with a population of CD8⁺CD11b⁺CD28⁺ lymphocytes. In the tumor tissue of all patients there was a positive correlation with a population of regulatory CD8⁺CD11b⁻CD28⁻ T cells. The immunoregulatory properties of sPD-1 and sPD-L1 were confirmed. Both sPD-1 and sPD-L1 levels were positively correlated with the number of suppressor CD8⁺CD11b⁻CD28⁻ T cells and negatively with the level of CD8 lymphocytes, CD8⁺CD11b⁺CD28⁺ cytotoxic/memory T cells, B cells and activated CD25 lymphocytes. Conclusion. The results of the study can make a certain contribution to the study of the prognostic significance of membrane and soluble forms of PD-1 and PD-L1, taking into account the peculiarities of their relationship with suppressor and effector populations of lymphocytes of systemic and local immunity.